CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

Open access
Cleare, Anthony J, Kerr-Gaffney, Jess, Goldsmith, Kimberley, Zenasni, Zohra, Yaziji, Nahel, Jin, Huajie, Colasanti, Alessandro, Geddes, John R, Kessler, David, McAllister-Williams, R Hamish, Young, Allan H, Barrera, Alvaro, Marwood, Lindsey, Taylor, Rachael W, Tee, Helena, Rucker, James, Williams, Ryan, Day, Camilla, Bountouni, Ilia, Juruena, Mario, Jelen, Luke, Edwards, Allison, Kan, Carol, Jairaj, Chaitra, Waterman, Lauren, McCutcheon, Robert, Gadelrab, Romayne, Patel, Rashmi, McLoughlin, Patrick, Day, Elana, Shah, Rupal, Cattell, Joseph, De Angel, Valeria, Incecik, Emma, Ancane, Anda, Oprea, Emmanuella, Ulrichsen, Andrea, Nikolova, Viktoriya, Mantingh, Tim, Tsapekos, Dimosthenis, Pickles, Andrew, Deitch, Daniel, Strawbridge, Rebecca, James, Kirsty, Romeo, Renee, Holland, Rachel, Watson, Stuart, Marey, Hossam, Ahuja, Niraj, Arebi, Eman, Armstrong, Daniel, Buruju, Dheeraj, Emechebe, Afamefuna, Esi, Oghenefejiro, Healicon, Jayne, Osman, Selma, Stageman, William, Sud, Neeti, Raj, Vineet, Burgess, Jennifer, Hutchinson, Jake, Nortey, Kimberley, Wilson, Susan, Hall, Wendy, Swift, Joe, Carr, Rosie, Hamilton, Jahnese, Reilly, Joe, Nair, Rajesh, Cowen, Philip, Browning, Michael, McKeown, Lucas, Mather, Sarah, Potts, Jen, Millar, Chris, Hollingsworth, Sarah, Dean, Rebecca, Morgan, Ceri, Harvey, Jade, Davies, Fay, Cipriani, Andrea, Attenburrow, Mary-Jane, Evans, Jonathan, Davies, Jonathan, Leach, Rwth, Roiz de S'a, Catherine, Pooley, Joanna, Emery, Guy, Gregory, Serena · 2025 · The Lancet Psychiatry

Abstract

BACKGROUND: Lithium and quetiapine are first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. We aimed to assess whether quetiapine augmentation therapy is more clinically effective and cost-effective than lithium for patients with treatment-resistant depression over 12 months. METHODS: We did this pragmatic, open-label, parallel-group, randomised controlled superiority trial at six National Health Service trusts in England. Eligible participants were adults (aged ≥18 years) with a current episode of major depressive disorder meeting DSM-5 criteria, with a score of 14 or higher on the 17-item Hamilton Depression Rating Scale at screening who had responded inadequately to two or more therapeutic antidepressant trials. Exclusion criteria included having a diagnosis of bipolar disorder or current psychosis. Participants were randomly assigned (1:1) to the decision to prescribe lithium or quetiapine, stratified by site, depression severity, and treatment resistance, using block randomisation with randomly varying block sizes. After randomisation, pre-prescribing safety checks were undertaken as per standard care before proceeding to trial medication initiation. The coprimary outcomes were depressive symptom severity over 12 months, measured weekly using the Quick Inventory of Depressive Symptomatology, and time to all-cause treatment discontinuation. Economic analyses compared the cost-effectiveness of the two treatments from both an NHS and personal social services perspective, and a societal perspective. Primary analyses were done in the intention-to-treat population, which included all randomly assigned participants. People with lived experience were involved in the trial. The trial is completed and registered with the International Standard Randomised Controlled Trial registry, ISRCTN16387615. FINDINGS: Between Dec 5, 2016, and July 26, 2021, 212 participants (97 [46%] male gender and 115 [54%] female gender) were randomly assigned to the decision to prescribe quetiapine (n=107) or lithium (n=105). The mean age of participants was 42·4 years (SD 14·0 years) and 188 (89%) of 212 participants were White, seven (3%) were of mixed ethnicity, nine (4%) participants were Asian, four (2%) were Black, three (1%) were of Other ethnicity, and ethnicity was not recorded for one (1%) participant. Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium. 32 serious adverse events were recorded in 18 participants, one of which was deemed possibly related to the trial medication in a female participant in the lithium group. The most common serious adverse event was overdose, occurring in three (3%) of 107 participants in the quetiapine group (seven events) and three (3%) of 105 participants in the lithium group (five events). INTERPRETATION: Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium. FUNDING: National Institute for Health and Care Research Health Technology Assessment programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(25)00028-8

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 18

Metadata

Authors
Cleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., Young, A. H., Barrera, A., Marwood, L., Taylor, R. W., Tee, H., Rucker, J., Williams, R., Day, C., Bountouni, I., Juruena, M., Jelen, L., Edwards, A., Kan, C., Jairaj, C., Waterman, L., McCutcheon, R., Gadelrab, R., Patel, R., McLoughlin, P., Day, E., Shah, R., Cattell, J., De Angel, V., Incecik, E., Ancane, A., Oprea, E., Ulrichsen, A., Nikolova, V., Mantingh, T., Tsapekos, D., Pickles, A., Deitch, D., Strawbridge, R., James, K., Romeo, R., Holland, R., Watson, S., Marey, H., Ahuja, N., Arebi, E., Armstrong, D., Buruju, D., Emechebe, A., Esi, O., Healicon, J., Osman, S., Stageman, W., Sud, N., Raj, V., Burgess, J., Hutchinson, J., Nortey, K., Wilson, S., Hall, W., Swift, J., Carr, R., Hamilton, J., Reilly, J., Nair, R., Cowen, P., Browning, M., McKeown, L., Mather, S., Potts, J., Millar, C., Hollingsworth, S., Dean, R., Morgan, C., Harvey, J., Davies, F., Cipriani, A., Attenburrow, M.-J., Evans, J., Davies, J., Leach, R., Roiz de S'a, C., Pooley, J., Emery, G., & Gregory, S.
Affiliations
  • King's College London (GB)
  • Brighton and Sussex Medical School (GB)
  • University of Oxford (GB)
  • University of Bristol (GB)
Corresponding author
Cleare, Anthony J
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2025-04
Volume
12
Issue
4
Pages
276-288
ISSN
2215-0366 (ISSN-L)
OpenAlex
W4408542506
Cited by
18
References
40
Citations by year
2026: 10 · 2025: 8
FWCI
10.10
Type
journal article
Language
en
Update notices
erratum (2025-06-01)
Open access
Licence
Locations
  • The Lancet Psychiatry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (publishedVersion, cc-by)
  • Research Portal (King's College London) (acceptedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Health Technology Assessment Programme (14/222/02)
  • Newcastle University (NIHR203309)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • King's College London
  • King's College Hospital NHS Foundation Trust
  • National Institute for Health and Care Research
  • Wellcome
  • NIHR Maudsley Biomedical Research Centre
  • NIHR Newcastle Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
treatment-resistant depression, lithium augmentation, major depressive disorder, antidepressant augmentation, cost-effectiveness, depression severity, treatment discontinuation, atypical antipsychotics, mood stabilizers, NHS perspective, societal perspective, long-term outcomes, National Health Service, patient and public involvement
MeSH terms
Quetiapine Fumarate, Adult, Antidepressive Agents, Cost-Benefit Analysis, Drug Therapy, Combination, Female, United Kingdom, Humans, Lithium, Male, Middle Aged, Antipsychotic Agents, Treatment Outcome, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. https://app.cochat.ai/papers/10.1016/s2215-0366(25)00028-8
The paper
Cleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., Young, A. H., Barrera, A., Marwood, L., Taylor, R. W., Tee, H., Rucker, J., Williams, R., Day, C., Bountouni, I., . . . Gregory, S. (2025). Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(25)00028-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.